Sandeep Saha, MD
Clinical Cardiac Electrophysiology · Salem, ORNPI 1679685101
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 85.5% of it on its own, with 36 other manufacturers making up the rest. Among clinical cardiac electrophysiology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $136.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$45K
- Boston Scientific$2K
- Abbott$2K
- Novartis$1K
- Biotronik Inc.$361
- Cordis US CORP.$310
- plus $2K from 31 others
What the payments were for
- Consulting fees$4,5009%
- Speaking & faculty fees$24,35747%
- Travel & lodging$12,64624%
- Food & beverage$10,45220%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 127 | $44,525 |
| Boston Scientific | 37 | $2,182 |
| Abbott | 38 | $1,682 |
| Novartis | 80 | $1,308 |
| Biotronik Inc. | 11 | $361 |
| Cordis US CORP. | 5 | $310 |
| AstraZeneca | 10 | $237 |
| Edwards Lifesciences | 2 | $151 |
| E.r. Squibb & Sons, L.L.C. | 6 | $133 |
| Johnson & Johnson | 8 | $124 |
| Pfizer | 6 | $109 |
| Cardiva Medical, Inc. | 3 | $108 |
| Amgen | 7 | $108 |
| Amarin Pharma, Inc. | 4 | $76 |
| Chiesi USA, Inc. | 3 | $73 |
| Impulse Dynamics (USA) Inc. | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Irhythm Technologies, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Inari Medical, Inc. | 1 | $24 |
| Elutia, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Teleflex LLC | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Cardinal Health 200 LLC | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Altathera Pharmaceuticals LLC | 1 | $12 |
| Penumbra, Inc. | 1 | $11 |
| Coala Life Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINQ II$1,820
- Reveal LINQ$1,554
- NA$720
- ENSITE PRECISION$183
- Arctic Front$157
- Confirm Rx$150
- MYNX CONTROL VENOUS$150
- GENERAL VASCULAR ACCESS$125
- PulseSelect$124
- WATCHMAN Access System$115
- Azure$114
How this compares
$52,077 in reported general payments places this provider in the 90th percentile of 37 clinical cardiac electrophysiology providers in Oregon.
See all clinical cardiac electrophysiology providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 652 | $697,782 |
| XareltoRivaroxaban | 120 | $124,862 |
| EntrestoSacubitril/Valsartan | 17 | $33,263 |
| Flecainide Acetate | 400 | $12,857 |
| Metoprolol Succinate | 474 | $7,685 |
| Amiodarone Hcl | 264 | $6,030 |
| Praluent PenAlirocumab | 13 | $6,016 |
| SotalolSotalol Hcl | 138 | $2,888 |
| Potassium Chloride | 99 | $2,605 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 62 | $2,356 |
| Atorvastatin Calcium | 145 | $1,822 |
| Carvedilol | 143 | $1,720 |
| Furosemide | 176 | $1,033 |
| Lisinopril | 113 | $971 |
| Losartan Potassium | 62 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $109 | $697,782652 claims |
| Johnson & JohnsonXarelto | $124 | $124,862120 claims |
| NovartisEntresto | $1,308 | $33,26317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 clinical cardiac electrophysiology providers in Oregon.
Other clinical cardiac electrophysiology in Salem
- Ashit PatelSalem$36K
- Wallace LaiSalem$8K
- Matthew FedorSalem$5K
- Eric PutzSalem$91
- Robert FlorekHood River$376K
- Jeff HsingCorvallis$89K
- Nathaniel McConkeyPortland$56K
- Jonathan LowyBend$46K
- Edward ChengGresham$39K
- Michael Charles TanPortland$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.